Autifony Therapeutics Limited
PrivateLast Round
Grant
Mar 15, 2017
Total Funding Raised
$43.01M
Company Overview
Autifony Therapeutics Limited operates in Healthcare & Life Sciences and is based in Stevenage. Its latest recorded funding round was a Grant round in March 2017.
Autifony Therapeutics Limited is a biotechnology company that develops novel medicines to treat rare genetic CNS disorders by using its ion channel drug discovery platform.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Revenue Share, Government Contracts
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Autifony Therapeutics Limited Comparables
Compare Autifony Therapeutics Limited with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Kaerus Bioscience | 81% | |
| Connecta Therapeutics | 80% | |
| Shionogi & Co. | 78% |
For institutional investors. Book with your work email.
Autifony Therapeutics Limited Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Mar 15, 2017 | ||||
| Series A Extension | Jul 10, 2015 | ||||
| Grant | Mar 1, 2014 | ||||
| Series A Extension | Jun 4, 2013 | ||||
| Series A | Aug 22, 2011 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Autifony Therapeutics Limited Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| SV Health Investors | Series A Extension, Series A |
| Innovate UK | Grant |
| Imperial Innovations | Series A |
| Medical Research Council | Grant |
| UCL Business | Series A Extension |
| Pfizer Ventures | Series A Extension |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 22, 2026
Monthly visitors grew 332% MoM, reaching 2.3K.
- Apr 17, 2026
Monthly visitors increased 30% MoM.
For institutional investors. Book with your work email.
Autifony Therapeutics Limited Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Autifony Therapeutics Limited's valuation, stock price, and market status.
Is Autifony Therapeutics Limited a public or private company?
Autifony Therapeutics Limited is a private company.
What is the current stock price of Autifony Therapeutics Limited?
Autifony Therapeutics Limited is a private company, so its shares have no public market price. Caplight tracks Autifony Therapeutics Limited's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Autifony Therapeutics Limited worth (valuation)?
Valuation information for Autifony Therapeutics Limited is not publicly available.
Can I buy Autifony Therapeutics Limited stock?
Autifony Therapeutics Limited shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Autifony Therapeutics Limited's last funding round?
Autifony Therapeutics Limited's most recent funding round was Grant on March 15, 2017.
Who are the main investors in Autifony Therapeutics Limited?
Key investors in Autifony Therapeutics Limited include SV Health Investors, Imperial Innovations.
Will Autifony Therapeutics Limited IPO soon?
No public IPO plans have been announced for Autifony Therapeutics Limited.
How can I track Autifony Therapeutics Limited secondary market activity?
Caplight tracks bids, offers, and trades in Autifony Therapeutics Limited's shares on secondary markets.